Jason Shawhan, Tesla’s director of manufacturing at Giga Texas, recently gave a rare talk about the facility’s existing operations and the company’s plans for the future. The executive shared the information during a keynote address at the State of Manufacturing conference and expo, which was held by the Austin Regional Manufacturers Association.
Tesla is the world’s most valuable automaker by market cap, and its CEO, Elon Musk, is one of the most visible chief executives in the auto industry. Despite this, Tesla has a reputation for being tight-lipped when it comes to the details of its operations. Rare appearances from high-ranking executives such as Shawhan, who serves as director of manufacturing at Gigafactory Texas, are therefore very interesting.
Shawhan did not disappoint, as he did share a number of important insights about the facility. As noted in a report from the Austin Business Journal, the executive confirmed that Giga Texas has become the second-largest private employer in the region because the factory currently employs over 20,000 workers today. This is a notable increase from the 12,277 employees that Tesla confirmed at the end of 2022. Considering Gigafactory Texas’ growth so far, it would appear that the facility would be outpacing Musk’s estimates.
It could be a new way to treat one of the more common and more frustrating symptoms of Alzheimer’s. A team at Johns Hopkins is leading a study on the drug, and you can get involved.
Leveraging Technology For Innovative, Patient-Centered Clinical Care — Dr. Peter Fleischut, MD — Group Senior Vice President And Chief Information & Transformation Officer, NewYork-Presbyterian Hospital
Dr. Peter M. Fleischut, M.D., is Group Senior Vice President and Chief Information and Transformation Officer at NewYork-Presbyterian (https://www.nyp.org/)where he oversees the strategic vision and management of enterprise information technology, lab operations, pharmacy operations, innovation, data and analytics, artificial intelligence, telemedicine, and cybersecurity.
Dr. Fleischut has led the development of the Hospital’s award-winning digital health services and the implementation of clinical operations at NewYork-Presbyterian David H. Koch Center, a world-class ambulatory care center. In his previous role as Senior Vice President and Chief Transformation Officer, he focused on creating a single electronic medical record across NewYork-Presbyterian and its affiliated medical schools, Weill Cornell Medicine and Columbia University Vagelos College of Physicians and Surgeons.
Dr. Fleischut also led efforts to standardize care across NYP’s ten hospitals and hundreds of clinics and doctor practices, and oversaw all aspects of Graduate Medical Education (GME) for programs across the NYP enterprise.
Joining NewYork-Presbyterian/Weill Cornell in 2006, Dr. Fleischut previously served as Medical Director of Operating Rooms, Deputy Quality Patient Safety Officer, founding Director of the Center for Perioperative Outcomes, Vice Chairman, Chief Medical Information Officer, Chief Innovation Officer and Chief Medical Operating Officer.
Revolutionizing Musculoskeletal Health Through Microcapsule Drug Delivery — Dr. @George R. Dodge, Ph.D. — CEO & Co-Founder — Mechano-Therapeutics LLC
Dr. George R. Dodge, Ph.D. is CEO & Co-Founder of Mechano-Therapeutics LLC (https://mechano-therapeutics.com/), a biotechnology company spun out from his lab, and the labs of his partners Dr. Rob Mauck and Dr. Daeyeon Lee, at the University of Pennsylvania, specializing in microcapsule development using proprietary microfluidics for drug encapsulation, with a mission to revolutionize musculoskeletal health using an innovative platform technology to enhance delivery of therapeutics for improving patient outcomes.
Dr. Dodge recently served on the faculty of Orthopaedic Surgery, Perelman School of Medicine, University of Pennsylvania; as Director, Philadelphia VA Shared Instrument Core; and Director, Translational Musculoskeletal Research Center, Philadelphia Crescenz Veterans Administration Medical Center, Department of Veteran Affairs.
Dr. Dodge has a B.S. (Biology) from Asbury College, a B.S. (Biology and Health Science / Public Health) from State University of New York, a Ph.D. (Biochemistry and Immunology) from McGill University, and did Post-Graduate work in Molecular and Cell Biology, at Thomas Jefferson University Department of Pathology and Cell Biology.
Dr. Dodge is an established investigator with a career long commitment to translational musculoskeletal research and in particular research focused on cartilage and chondrocyte biology, extracellular matrix and research related to osteoarthritis.
We live in a tech-enabled world, but for organizations to advance world-changing innovations, they need skilled people who can build, install, and maintain the systems that underlie them. Finding that talent is one of the biggest ongoing problems — and opportunities — in tech.
The P2PInfect botnet worm is going through a period of highly elevated activity volumes starting in late August and then picking up again in September 2023.
P2PInfect was first documented by Unit 42 in July 2023 as a peer-to-peer malware that breaches Redis instances using a remote code execution flaw on internet-exposed Windows and Linux systems.
Cado Security researchers who have been following the botnet since late July 2023, report today seeing global activity, with most breaches impacting systems in China, the United States, Germany, Singapore, Hong Kong, the UK, and Japan.
It lets researchers extract pixel-by-pixel information from nanoscale.
The nanoscale refers to a length scale that is extremely small, typically on the order of nanometers (nm), which is one billionth of a meter. At this scale, materials and systems exhibit unique properties and behaviors that are different from those observed at larger length scales. The prefix “nano-” is derived from the Greek word “nanos,” which means “dwarf” or “very small.” Nanoscale phenomena are relevant to many fields, including materials science, chemistry, biology, and physics.
Living things act with purpose. But where does purpose come from? How do humans make sense of their relation to the world and realize their ability to effect change? These fundamental questions of agency – acting with purpose – have perplexed some of the greatest minds in history including Sir Isaac Newton, Charles Darwin, Erwin Schrödinger, and Niels Bohr.
New research from Florida Atlantic University reveals groundbreaking insight into the origins of agency using an unusual and largely untapped source – human babies. Since goal-directed action appears in the first months of human life, the FAU research team used young infants as a test field to understand how spontaneous movement transforms into purposeful action.
For the study, infants began the experiment as disconnected observers. However, when researchers tethered one of the infants’ feet to a crib-mounted baby mobile, infants discovered they could make the mobile move. To catch this moment of realization like lightning in a bottle, researchers measured infant and mobile movement in 3D space using cutting-edge motion capture technology to uncover dynamic and coordinative features marking the “birth of agency.”
